Market Closed -
Nasdaq
04:00:00 2024-05-10 pm EDT
|
5-day change
|
1st Jan Change
|
15.5
USD
|
+0.13%
|
|
-1.59%
|
+44.86%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
102
|
156.8
|
26.8
|
457.2
|
929.1
|
-
|
-
|
Enterprise Value (EV)
1 |
102
|
156.8
|
26.8
|
457.2
|
929.1
|
929.1
|
929.1
|
P/E ratio
|
-1.84
x
|
-6.06
x
|
-0.72
x
|
-1.99
x
|
-8.58
x
|
-6.9
x
|
-5.37
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
32.6
x
|
96.8
x
|
290
x
|
63
x
|
EV / Revenue
|
-
|
-
|
-
|
32.6
x
|
96.8
x
|
290
x
|
63
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-8.02
x
|
-
|
-
|
-54.4
x
|
-21.6
x
|
-13.1
x
|
-16.6
x
|
FCF Yield
|
-12.5%
|
-
|
-
|
-1.84%
|
-4.63%
|
-7.64%
|
-6.03%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
10,542
|
12,100
|
12,129
|
42,730
|
59,943
|
-
|
-
|
Reference price
2 |
9.680
|
12.96
|
2.210
|
10.70
|
15.50
|
15.50
|
15.50
|
Announcement Date
|
3/25/21
|
3/28/22
|
3/16/23
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
14.02
|
9.6
|
3.2
|
14.75
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
-12.26
|
-25.2
|
-36.9
|
-28.73
|
-101.7
|
-144.4
|
-179.8
|
Operating Margin
|
-
|
-
|
-
|
-
|
-204.94%
|
-1,059.77%
|
-4,512.98%
|
-1,219.36%
|
Earnings before Tax (EBT)
1 |
-
|
-17.84
|
-
|
-36.9
|
-106.8
|
-97.46
|
-138.6
|
-177.2
|
Net income
1 |
-10.44
|
-17.84
|
-24.71
|
-37.52
|
-106.8
|
-104
|
-144.1
|
-192.7
|
Net margin
|
-
|
-
|
-
|
-
|
-761.92%
|
-1,083.04%
|
-4,502.11%
|
-1,306.88%
|
EPS
2 |
-0.3200
|
-5.260
|
-2.140
|
-3.090
|
-5.380
|
-1.806
|
-2.248
|
-2.888
|
Free Cash Flow
1 |
-
|
-12.72
|
-
|
-
|
-8.399
|
-43
|
-71
|
-56
|
FCF margin
|
-
|
-
|
-
|
-
|
-59.92%
|
-447.92%
|
-2,218.75%
|
-379.76%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
9/9/20
|
3/25/21
|
3/28/22
|
3/16/23
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
2.364
|
-
|
-
|
3.826
|
2.8
|
2.6
|
2.6
|
1.6
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-7.723
|
-7.844
|
-11.65
|
-8.926
|
-8.534
|
-7.787
|
-4.471
|
-
|
-
|
-13.85
|
-27.03
|
-23.13
|
-24.08
|
-27.75
|
-40
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-189.13%
|
-
|
-
|
-362.02%
|
-965.47%
|
-889.66%
|
-926.07%
|
-1,734.12%
|
-
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-
|
-
|
-8.533
|
-7.786
|
-4.27
|
-
|
-
|
-92.63
|
-26.28
|
-21.76
|
-22.81
|
-26.59
|
-37.8
|
Net income
1 |
-7.72
|
-7.852
|
-11.65
|
-8.924
|
-9.155
|
-7.786
|
-4.27
|
-
|
-4.345
|
-92.63
|
-39.24
|
-19.51
|
-20.81
|
-24.37
|
-37.8
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-180.63%
|
-
|
-
|
-2,421.17%
|
-1,401.51%
|
-750.28%
|
-800.36%
|
-1,523.31%
|
-
|
EPS
2 |
-0.6500
|
-0.6500
|
-0.9600
|
-0.7400
|
-0.7500
|
-0.6400
|
-0.3500
|
-0.4600
|
-0.3600
|
-4.220
|
-0.6940
|
-0.3480
|
-0.3600
|
-0.4200
|
-0.6700
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/15/21
|
3/28/22
|
5/12/22
|
8/5/22
|
11/14/22
|
3/16/23
|
5/5/23
|
8/9/23
|
11/9/23
|
3/28/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-12.7
|
-
|
-
|
-8.4
|
-43
|
-71
|
-56
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-23.9%
|
-26%
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-21.2%
|
-23.7%
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
490.4
|
607.9
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
0.59
|
0.08
|
0.25
|
0.83
|
1.27
|
1.97
|
2.75
|
Capex / Sales
|
-
|
-
|
-
|
-
|
5.93%
|
13.19%
|
61.46%
|
18.65%
|
Announcement Date
|
9/9/20
|
3/25/21
|
3/28/22
|
3/16/23
|
3/28/24
|
-
|
-
|
-
|
Last Close Price
15.5
USD Average target price
32.5
USD Spread / Average Target +109.68% Consensus |
1st Jan change
|
Capi.
|
---|
| +44.86% | 929M | | +3.91% | 109B | | +10.87% | 105B | | +1.28% | 22.25B | | -13.14% | 22.09B | | -7.05% | 18.68B | | -38.36% | 17.58B | | -10.66% | 16.85B | | +3.75% | 13.76B | | +36.70% | 12.46B |
Bio Therapeutic Drugs
|